Parenteral immunization with a glycoconjugate vaccine containing the O157 antigen of <i>Escherichia coli </i> O157:H7 elicits a systemic humoral immune response in mice, but fails to prevent colonization by the pathogen

The results of the present study show that whereas both BALB/c and C57BL/6 mice parenterally inoculated with a horse serum albumin - Escherichia coli O157 antigen conjugate vaccine develop systemic, specific antibodies to the carrier protein, only the former mice routinely develop antibodies to the carbohydrate O157 moiety. However, little convincing evidence was found to show that these antibodies transuded into the intestinal tract either naturally or in response to an oral inoculum of the pathogen. Moreover, this vaccination procedure failed to protect mice against intestinal colonization following oral challenge with the pathogen. Thus, the results of this study suggest that parenteral vaccination might be an unsuitable strategy for combatting E. coli O157:H7 organisms located in the gut.Key words: Escherichia coli, glycoconjugate vaccine, mice.

Download Full-text

Oral immunization of mice with a glycoconjugate vaccine containing the O157 antigen of Escherichia coli O157:H7 admixed with cholera toxin fails to elicit protection against subsequent colonization by the pathogen

Canadian Journal of Microbiology ◽

10.1139/w99-142 ◽

2000 ◽

Vol 46 (3) ◽

pp. 283-290 ◽

Cited By ~ 9

Author(s):

J Wayne Conlan ◽

Rhonda KuoLee ◽

Ann Webb ◽

Andrew D Cox ◽

Malcolm B Perry

Keyword(s):

Escherichia Coli ◽

Immune Response ◽

Cholera Toxin ◽

Horse Serum ◽

Oral Immunization ◽

Escherichia Coli O157 ◽

E Coli ◽

Humoral Immune ◽

Unvaccinated Control ◽

Glycoconjugate Vaccine

It has been postulated that a humoral immune response directed against the O157 antigen of Escherichia coli O157:H7, and expressed in the intestine, might afford protection from colonization and consequent infection by this enteric pathogen. The present study was conducted to determine whether such an immune response can be experimentally generated in mice. To this end, mice were orally immunized with a glycoconjugate vaccine consisting of horse serum albumin and the O157 polysaccharide admixed with the mucosal adjuvant, cholera toxin. Mice consistently developed robust local and systemic immune responses to the cholera toxin adjuvant, but were far from uniformly reactive to the test vaccine. Moreover, vaccinated mice were as susceptible to transient intestinal colonization following challenge with an isolate of E. coli O157:H7 as unvaccinated control mice. These results indicate that this vaccination approach is unlikely to be straightforward in target bovine or human hosts.Key words: Escherichia coli O157:H7, glycoconjugate vaccine, mucosal immunity, mice.

Download Full-text

Differences in systemic humoral immune response among Balb/c mice administered with probiotic, LPS Escherichia coli, and probiotic-LPS E. coli

Iranian Journal of Microbiology ◽

10.18502/ijm.v11i4.1466 ◽

2019 ◽

Author(s):

Kurniawan Taufiq Kadafi ◽

Satrio Wibowo

Keyword(s):

Escherichia Coli ◽

Immune Response ◽

Humoral Immune Response ◽

Control Group ◽

E Coli ◽

Humoral Immune ◽

Treatment Regimens ◽

Humoral Immune Responses ◽

Group 4 ◽

Group 2

Background and Objectives: The aim of this study was to compare the systemic humoral immune responses, including IgE, IgA, IgG and IgM levels in Balb/c mice administered a probiotic, LPS derived from Escherichia coli (E.coli), and probiot- ic-LPS derived from E. coli. Materials and Methods: Thirty-two male Balb/c mice, 10-12 weeks of age with body weight ranging from 30-40 g were randomly divided into four experimental groups (n=8). The treatment regimens were as follows: Group 1, mice did not receive LPS or probiotic (control group); Group 2, mice received only LPS on the first day; Group 3, mice received probi- otic for 7 days; Group 4, mice received LPS on the first day, and then continued, with probiotic for 7 days. The mice were observed for 8 days, and then, euthanized the next day (day 9). The serum was collected, and the levels of IgE, IgA, IgG and IgM were measured using ELISA. Results: The humoral immune response was higher in the presence of a probiotic compared to that in the control; IgE (9.02 ± 0.58 units/ml, p=0.000), IgA (3.26 ± 0.99 units/ml, p=0.316), IgG (7.29 ± 0.24 units/ml, p=0.000), and IgM (4.01 ± 2.98 units/ml, p=0.505). When administered with LPS E. coli along with probiotic, the humoral immune response was the highest; IgE (10.68 ± 1.63 units/ml, p=0.000), IgA (8.34 ± 1.47 units/ml, p=0.000), IgG (9.96 ± 0.98 units/ml, p=0.000), and IgM (4.31 ± 1.05 units/ml, p=0.319) compared to the control group. Conclusion: Probiotic-LPS derived from E. coli treatment induced a higher humoral immune response (highest IgE, IgA, IgG and IgM levels) compared to treatment with probiotic only.

Download Full-text